Hiroshi Sakamoto

Summary

Affiliation: Chugai Pharmaceutical Co
Country: Japan

Publications

  1. doi request reprint CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant
    Hiroshi Sakamoto
    Kamakura Research Laboratories, Chugai Pharmaceutical Co, Ltd, 200 Kajiwara, Kamakura, Kanagawa 247 8530, Japan
    Cancer Cell 19:679-90. 2011
  2. ncbi request reprint Host sphingolipid biosynthesis as a target for hepatitis C virus therapy
    Hiroshi Sakamoto
    Kamakura Research Laboratories, Chugai Pharmaceutical Co Ltd, 200 Kajiwara, Kamakura, Kanagawa 247 8530, Japan
    Nat Chem Biol 1:333-7. 2005
  3. doi request reprint Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802)
    Kazutomo Kinoshita
    Research Division, Chugai Pharmaceutical Co, Ltd, 200 Kajiwara, Kamakura, Kanagawa 247 8530, Japan
    Bioorg Med Chem 20:1271-80. 2012
  4. doi request reprint Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity
    Nobuya Ishii
    Kamakura Research Laboratory, Research Division, Chugai Pharmaceutical Co, Ltd, Kamakura, Japan
    Cancer Res 73:4050-60. 2013
  5. doi request reprint 9-substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as highly selective and potent anaplastic lymphoma kinase inhibitors
    Kazutomo Kinoshita
    Research Division, Chugai Pharmaceutical Co, Ltd, 200 Kajiwara, Kamakura, Kanagawa 247 8530, Japan
    J Med Chem 54:6286-94. 2011
  6. doi request reprint Design and evaluation of azaindole-substituted N-hydroxypyridones as glyoxalase I inhibitors
    Takashi Chiba
    Research Division, Chugai Pharmaceutical Co, Ltd, 200 Kajiwara Kamakura, Kanagawa 247 8530, Japan
    Bioorg Med Chem Lett 22:7486-9. 2012
  7. doi request reprint Discovery of 6-benzyloxyquinolines as c-Met selective kinase inhibitors
    Hiroki Nishii
    Department of Chemistry Research 2, Chugai Pharmaceutical Co, Ltd, 200 Kajiwara, Kamakura, Kanagawa 247 8530, Japan
    Bioorg Med Chem Lett 20:1405-9. 2010
  8. pmc An orally available, small-molecule interferon inhibits viral replication
    Hideyuki Konishi
    Kamakura Research Laboratories, Chugai Pharmaceutical Co Ltd, Kamakura, Kanagawa, Japan
    Sci Rep 2:259. 2012
  9. doi request reprint Enantioselective synthesis of derivatives and structure-activity relationship study in the development of NA255 as a novel host-targeting anti-HCV agent
    Ken ichi Kawasaki
    Research Division, Chugai Pharmaceutical Co, Ltd, 200 Kajiwara, Kamakura, Kanagawa 247 8530, Japan Electronic address
    Bioorg Med Chem Lett 23:336-9. 2013
  10. doi request reprint Discovery of novel tetracyclic compounds as anaplastic lymphoma kinase inhibitors
    Kazutomo Kinoshita
    Kamakura Research Laboratories, Chugai Pharmaceutical Co Ltd, Kamakura, Kanagawa, Japan
    Bioorg Med Chem Lett 21:3788-93. 2011

Collaborators

  • Jun Ohwada
  • Michinori Kohara
  • Takaaki Miura
  • Neal Rosen
  • Toshiyuki Sakai
  • Yutaka Matsuda
  • Naoki Harada
  • Hidetoshi Shindoh
  • Graham R Foster
  • Yoshiyuki Ono
  • Takashi Emura
  • Kazutomo Kinoshita
  • Takuo Tsukuda
  • Yuko Aoki
  • Nobuo Shimma
  • Takamitsu Kobayashi
  • Kohsuke Asoh
  • Nobuhiro Oikawa
  • Takashi Chiba
  • Hatsuo Kawada
  • Toshiyuki Tsukaguchi
  • Noriyuki Furuichi
  • Toshiya Ito
  • Ken ichi Kawasaki
  • Nobuya Ishii
  • Asao Katsume
  • Kazuhiro Ohara
  • Masayuki Sudoh
  • Atsunori Ohta
  • Mikio Arisawa
  • Hideyuki Konishi
  • Kenji Takanashi
  • Sousuke Hara
  • Takuho Miyagi
  • Hiroshi Koyano
  • Takaaki A Fukami
  • Kenji Morikami
  • Hiroki Nishii
  • Susumu Komiyama
  • Hitoshi Iikura
  • Eric W Joseph
  • Yasushi Tomii
  • Masahiro Aoki
  • Yukako Tachibana-Kondo
  • Yoshihiro Sowa
  • Yasuaki Matsubara
  • Miyako Masubuchi
  • Fumio Watanabe
  • Toshihiro Aoki
  • Tadakatsu Hayase
  • Takeshi Murata
  • Poulikos I Poulikakos
  • Kohichi Okamato
  • Kouhei Koyama
  • Hiroshi Fukuda
  • Koichi Okamoto
  • Machiko Irie
  • Hiroshi Ohmori
  • Kazumi Morikawa
  • Motooki Ashihara
  • Yuichi Hirata
  • Hitoshi Yoshino
  • Natsuko Hada
  • Yusuke Ohmori
  • William Alazawi
  • Min Jeong Park
  • Kazuo Hattori
  • Woo Sang Hong
  • Shota Tanaka
  • Kwangseok Ko

Detail Information

Publications10

  1. doi request reprint CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant
    Hiroshi Sakamoto
    Kamakura Research Laboratories, Chugai Pharmaceutical Co, Ltd, 200 Kajiwara, Kamakura, Kanagawa 247 8530, Japan
    Cancer Cell 19:679-90. 2011
    ..Our results support the potential for clinical evaluation of CH5424802 for the treatment of patients with ALK-driven tumors...
  2. ncbi request reprint Host sphingolipid biosynthesis as a target for hepatitis C virus therapy
    Hiroshi Sakamoto
    Kamakura Research Laboratories, Chugai Pharmaceutical Co Ltd, 200 Kajiwara, Kamakura, Kanagawa 247 8530, Japan
    Nat Chem Biol 1:333-7. 2005
    ..Thus, NA255 is a new anti-HCV replication inhibitor that targets host lipid rafts, suggesting that inhibition of sphingolipid metabolism may provide a new therapeutic strategy for treatment of HCV infection...
  3. doi request reprint Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802)
    Kazutomo Kinoshita
    Research Division, Chugai Pharmaceutical Co, Ltd, 200 Kajiwara, Kamakura, Kanagawa 247 8530, Japan
    Bioorg Med Chem 20:1271-80. 2012
    ..In this work, we optimized the side-chains and identified highly selective, orally active and potent ALK inhibitor CH5424802 (18a) as the clinical candidate...
  4. doi request reprint Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity
    Nobuya Ishii
    Kamakura Research Laboratory, Research Division, Chugai Pharmaceutical Co, Ltd, Kamakura, Japan
    Cancer Res 73:4050-60. 2013
    ..CH5126766 represents a new type of MEK inhibitor that causes MEK to become a dominant-negative inhibitor of RAF and that, in doing so, may have enhanced therapeutic activity in ERK-dependent tumors with mutant RAS...
  5. doi request reprint 9-substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as highly selective and potent anaplastic lymphoma kinase inhibitors
    Kazutomo Kinoshita
    Research Division, Chugai Pharmaceutical Co, Ltd, 200 Kajiwara, Kamakura, Kanagawa 247 8530, Japan
    J Med Chem 54:6286-94. 2011
    ..8 nM. The compound also displayed significant antitumor efficacy in an established ALK fusion gene-positive anaplastic large-cell lymphoma (ALCL) xenograft model in mice without body weight loss...
  6. doi request reprint Design and evaluation of azaindole-substituted N-hydroxypyridones as glyoxalase I inhibitors
    Takashi Chiba
    Research Division, Chugai Pharmaceutical Co, Ltd, 200 Kajiwara Kamakura, Kanagawa 247 8530, Japan
    Bioorg Med Chem Lett 22:7486-9. 2012
    ....
  7. doi request reprint Discovery of 6-benzyloxyquinolines as c-Met selective kinase inhibitors
    Hiroki Nishii
    Department of Chemistry Research 2, Chugai Pharmaceutical Co, Ltd, 200 Kajiwara, Kamakura, Kanagawa 247 8530, Japan
    Bioorg Med Chem Lett 20:1405-9. 2010
    ....
  8. pmc An orally available, small-molecule interferon inhibits viral replication
    Hideyuki Konishi
    Kamakura Research Laboratories, Chugai Pharmaceutical Co Ltd, Kamakura, Kanagawa, Japan
    Sci Rep 2:259. 2012
    ..Our study highlights the importance of an orally active IFN-like agent, both as a therapy for antiviral infections and as a potential IFN substitute...
  9. doi request reprint Enantioselective synthesis of derivatives and structure-activity relationship study in the development of NA255 as a novel host-targeting anti-HCV agent
    Ken ichi Kawasaki
    Research Division, Chugai Pharmaceutical Co, Ltd, 200 Kajiwara, Kamakura, Kanagawa 247 8530, Japan Electronic address
    Bioorg Med Chem Lett 23:336-9. 2013
    ..The structure-activity relationship of the NA255 derivatives and rat pharmacokinetic profiles of the representative compounds are disclosed...
  10. doi request reprint Discovery of novel tetracyclic compounds as anaplastic lymphoma kinase inhibitors
    Kazutomo Kinoshita
    Kamakura Research Laboratories, Chugai Pharmaceutical Co Ltd, Kamakura, Kanagawa, Japan
    Bioorg Med Chem Lett 21:3788-93. 2011
    ..Among them, compound 27 showed strong cytotoxicity against KARPAS-299 with an IC(50) value of 21 nM and significant antitumor efficacy in ALK fusion-positive blood and solid cancer xenograft models in mice without body weight loss...